Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN3009 first-in-human study in relapsed or refractory B-cell non-Hodgkin lymphoma
NL-OMON56143Phase 1Active, not recruiting
- Sponsor
- Genmab
- Start
- Jan 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of ivicentamab and epcoritamab in mature B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL) and 1 more (4 arms), sponsored by Genmab. Primary endpoints: Rate of dose-limiting toxicities, Safety and tolerability and 2 more. Started Jan 2021; status: active, not recruiting.
02
Drugs
ivicentamabepcoritamab
03
Conditions
mature B-cell lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON56143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56143.